Research Highlight | Published:

THERAPY

Testing a novel dual receptor agonist for treatment of type 2 diabetes mellitus

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Frias, J. P. et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet https://doi.org/10.1016/S0140-6736(18)32260-8 (2018)

    Download references

    Author information

    Correspondence to Claire Greenhill.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark